Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2- negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first-line chemotherapy and the characteristics of the patients who benefited from eribulin remain unclear. | Nakamoto et al. BMC Cancer 2022 22 31 https doi.org 10.1186 s12885-021-09137-0 RESEARCH ARTICLE Open Access Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer a multicenter retrospective study Shogo Nakamoto1 2 Junichiro Watanabe1 Shoichiro Ohtani3 Satoshi Morita4 and Masahiko Ikeda2 Abstract Background Eribulin methylate eribulin improved the overall survival OS of eribulin-treated patients with HER2- negative advanced breast cancer ABC in prospective and retrospective studies. However the effect of eribulin on OS as first-line chemotherapy and the characteristics of the patients who benefited from eribulin remain unclear. Methods Between January 2011 and December 2016 301 patients with HER2-negative ABC who started first-line chemotherapy at 3 institutions were retrospectively evaluated for OS from the initiation of first-line chemotherapy. Results We identified 172 patients 119 estrogen receptor-positive ER 47 ER 6 unknown who received eribulin eribulin group and 129 patients 92 ER 31 ER 6 unknown who did not receive eribulin non-eribulin group . The median OS from the initiation of first-line chemotherapy in the two groups was not statistically significant 869 vs. 744 days P 0.47 log-rank however in patients who received eribulin in later lines 3rd-line and who had a history of perioperative chemotherapy with anthracycline- and or taxane-based regimens the median OS improved 1001 vs. 744 days P 0.037 and 834 vs. 464 days respectively P 0.032 respectively Wilcoxon . Multivariate analyses revealed that a history of perioperative chemotherapy with anthracycline- and or taxane-based regimens was a pre- dictive factor hazard ratio 0.39 95 confidence interval 0.21 0.70 for OS. Conclusions This study successfully identified subgroups of HER2 ABC patients with improved OS by eribulin therapy. Selecting patients according to their background and line of treatment will maximize the efficacy of .
